title: ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?
abstract: The response definitions proposed by the European Leukemia Net (ELN) have been recently modified. We evaluated the new criteria for de novo imatinib (400 mg/d) chronic phase chronic myeloid leukemia (CP-CML) patients. Response status according to the 2009 and 2013 criteria were determined in 180 unselected patients. Outcome of the subgroups of patients were then compared. The 180 patients were classified as optimal responders (OR2009; n = 113, 62.7%), suboptimal responders (SOR2009; n = 47, 26.1%) and failures (FAIL2009; n = 20, 11.1%) according to the 2009 ELN criteria and optimal responders (OR2013; n = 77, 42.7%), warnings (WAR2013; n = 59, 32.7%), and failures (FAIL2013; n = 44, 24.4%) according to the 2013 ELN criteria. No difference in terms of outcome was observed between OR2009 patients who became WAR2013 when compared with OR2013 patients. When compared with FAIL2009 patients, SOR2009 patients who became WAR2013 had better EFS, FFS, PFS, and OS. No difference was observed in PFS or OS in SOR2009 patients who became FAIL2013. The 2013 ELN response status criteria have improved patients classification in terms of response status. However, in our patient population this improvement is related to a better definition of failure rather than that of optimal response for CP-CML patients treated with IM frontline therapy.
authors.affiliation: Hematology Department, Institut Bergonié, Bordeaux, France.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Etienne
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Dulucq
authors.forename: Axelle
authors.initials: A
authors.lastname: Lascaux
authors.forename: Anna
authors.initials: A
authors.lastname: Schmitt
authors.forename: Audrey
authors.initials: A
authors.lastname: Bidet
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Fort
authors.forename: Eric
authors.initials: E
authors.lastname: Lippert
authors.forename: Caroline
authors.initials: C
authors.lastname: Bureau
authors.forename: Didier
authors.initials: D
authors.lastname: Adiko
authors.forename: Sandrine
authors.initials: S
authors.lastname: Hayette
authors.forename: Josy
authors.initials: J
authors.lastname: Reiffers
authors.forename: Franck-Emmanuel
authors.initials: FE
authors.lastname: Nicolini
authors.forename: François-Xavier
authors.initials: FX
authors.lastname: Mahon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000145:classification / Q000379:methods; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D017211:Treatment Failure; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate